BeiGene announced that its operating income in 2025 is expected to be between RMB 35.2 billion and RMB 38.1 billion. The strong growth in revenue is mainly due to BeiGene's leading position in the United States and its continued expansion in Europe and other important markets around the world. At the same time, based on the company's product portfolio and improved production efficiency, the gross profit margin is expected to be in the median range of 80% to 90% in 2025. It is expected that the total R&D expenses, sales and administrative expenses in 2025 will be between RMB 29.5 billion and RMB 31.9 billion.